Biotech to drive biggest cancer advancements in decades – report

A new report on the prospects of immunotherapy treatments has identified smaller, nimble biotechs and early stage companies as the single biggest factor behind the next generation of approaches in development. The report concludes that the next five years will be the most promising in the fight against cancer with immunotherapies – such as CAR-T and moderating T-Cell approaches, and innate immunity therapies – delivering far better patient outcomes. The Inside Perspectives: Will Immunotherapy Knock Out Cancer? report, from WuXi AppTec, predicts that over the next 10-years we will see significantly greater breakthroughs as the industry’s understanding of the immune system improves. There are currently more than 130 biotechs working on new therapies – in addition to 20 big pharmas – and it is believed the smaller companies are more aggressively bringing newer innovations to market.